Dirk Weber

Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer

Nicoletta Colombo, E. Kutarska, Meletios Α. Dimopoulos et al. · Journal of Clinical Oncology · 2012 · 120 citations

Efficient Synthesis of Empagliflozin, an Inhibitor of SGLT-2, Utilizing an AlCl₃-Promoted Silane Reduction of a β-Glycopyranoside

Xiao‐jun Wang, Li Zhang, Denis Byrne et al. · Organic Letters · 2014 · 102 citations

Glycobiology, Efficient Production Synthesis, Efficient Synthesis +16

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

Ullrich Graeven, B. Kremer, Th Südhoff et al. · British Journal of Cancer · 2006 · 99 citations · Full text

A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)

Christian Kollmannsberger, Marcus M. Schittenhelm, Friedemann Honecker et al. · Annals of Oncology · 2006 · 94 citations · Full text

Medicine, Immunology, Pathology +6

Pleiotrophin can be rate-limiting for pancreatic cancer cell growth.

Dirk Weber, H.-J. Klomp, Frank Czubayko et al. · PubMed · 2000 · 65 citations

Tumor Biology, Pancreatic Cancer, Gastrointestinal Oncology +11